Breast Cancer: Targets and Therapy (Nov 2024)
Feasibility Study of Pyrrolitinib-Based Dual-Target Therapy for Neoadjuvant Treatment of HER2-Positive Breast Cancer Patients
Abstract
Feng Zhao,1 Hongzhen Zhang2 1The First Hospital of Anhui University of Science and Technology, Huainan, Anhui, People’s Republic of China; 2Anhui University of Science and Technology, Huainan, Anhui, People’s Republic of ChinaCorrespondence: Hongzhen Zhang, Anhui University of Science and Technology, Huainan, Anhui, People’s Republic of China, Tel +8613155438639, Email [email protected]: HER2-positive breast cancer is one of the high-risk subtypes of breast cancer for which dual-targeted therapy has become an important treatment option. However, for some patients, complete control of the disease is still not possible and additional treatment is required. Pyrrolitinib, an inhibitor of ALK and MET, has shown promising efficacy in breast cancer treatment. The aim of this study was to investigate the feasibility of adjuvant intensive therapy with pyrrolitinib in the treatment of HER2-positive breast cancer tumors.Materials and Methods: Twenty-eight patients with HER2-positive breast cancer who were treated at the Breast Surgery Department of the Provincial Hospital of Weihai City, Shandong Province, China, between January 1, 2019, and January 1, 2023, were selected for this study. All of these patients received dual-targeted therapy with the addition of pyrrolitinib therapy adjuvant intensive therapy. We recorded data on the patients’ basic information, pathological characteristics, treatment regimens, effects of treatment regimens, and adverse reactions, and statistically analyzed them.Results: Of the 28 patients with HER2-positive breast cancer, all of them were added to adjuvant intensive therapy with pyrrolitinib. After examination of the samples during treatment, the breast cancer mass had been significantly reduced with the assistance of pyrrolitinib. In addition, no serious adverse reactions were found.Conclusion: Adjuvant intensification of pyrrolitinib in the treatment of HER2-positive breast cancer tumors is feasible. The results of this study suggest that pyrrolitinib is a safe and effective therapeutic option that can significantly improve the outcome of HER2-positive breast cancer. More studies are needed to further validate this finding.Keywords: HER2-positive breast cancer, dual-target therapy, pyrrolitinib, adjuvant intensive therapy, feasibility study
